Ratings by Wells Fargo (Derek Archila)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/3/2026 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/2/2026 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | argenx SE | ARGX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/17/2026 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/13/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2026 | Exelixis | EXEL | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/11/2026 | Incyte | INCY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/3/2026 | Viridian Therapeutic | VRDN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 1/29/2026 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/20/2026 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 1/20/2026 | Incyte | INCY | Downgrade | Equal Weight (Overweight) |
106.21 (95.94) |
-9.67% | Details | |
| 1/8/2026 | Monte Rosa Therapeutics | GLUE | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Disc Medicine | IRON | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/16/2025 | Monte Rosa Therapeutics | GLUE | Upgrade | Overweight (Equal Weight) |
16.45 (17.80) |
8.21% | Details | |
| 12/12/2025 | Sutro Biopharma | STRO | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 12/9/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 12/8/2025 | Incyte | INCY | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/8/2025 | ORIC Pharmaceuticals | ORIC | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2025 | Annexon Biosciences | ANNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Septerna Inc | SEPN | Upgrade | Overweight (Equal Weight) |
19.24 (28.78) |
49.58% | Details | |
| 11/11/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/11/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 11/6/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2025 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/29/2025 | Incyte | INCY | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/23/2025 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/21/2025 | Exelixis | EXEL | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/20/2025 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 10/20/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 10/15/2025 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Equal Weight) |
23.15 (20.07) |
-13.3% | Details | |
| 10/8/2025 | Kyverna Therapeutics Inc | KYTX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/24/2025 | Soleno Therapeutics Inc. | SLNO | Maintain | Overweight (N/A) |
|
Details | ||
| 9/23/2025 | C4 Therapeutics | CCCC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2025 | Celldex Therapeutics | CLDX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/20/2025 | Soleno Therapeutics Inc. | SLNO | New Coverage | Overweight (N/A) |
66.81 (39.68) |
-40.61% | Details | |
| 8/12/2025 | Sutro Biopharma | STRO | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/12/2025 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (Underweight) |
|
Details | ||
| 8/7/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/7/2025 | Viridian Therapeutic | VRDN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 8/7/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/6/2025 | Incyte | INCY | Upgrade | Overweight (Equal Weight) |
77.72 (106.21) |
36.66% | Details | |
| 6/26/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/25/2025 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (Underweight) |
|
Details | ||
| 6/17/2025 | Blueprint Medicines | BPMC | Downgrade | Equal Weight (Overweight) |
128.25 (129.46) |
0.94% | Details | |
| 6/3/2025 | Kymera Therapeutics | KYMR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/2/2025 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/16/2025 | Septerna Inc | SEPN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/9/2025 | Q32 Bio Inc. | QTTB | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/8/2025 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/2/2025 | Arvinas Inc. | ARVN | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/9/2025 | Nurix | NRIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/28/2025 | Septerna Inc | SEPN | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/24/2025 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (Underweight) |
|
Details | ||
| 2/24/2025 | Exelixis | EXEL | Downgrade | Equal Weight (Overweight) |
36.85 (41.55) |
12.75% | Details | |
| 2/18/2025 | Septerna Inc | SEPN | Downgrade | Equal Weight (Overweight) |
12.96 (28.78) |
122.07% | Details | |
| 1/30/2025 | Zentalis Pharmaceuticals | ZNTL | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2024 | Zymeworks | ZYME | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2024 | C4 Therapeutics | CCCC | Upgrade | Overweight (Equal Weight) |
3.65 (3.04) |
-16.71% | Details | |
| 12/19/2024 | Viridian Therapeutic | VRDN | Downgrade | Equal Weight (Overweight) |
18.93 (28.34) |
49.71% | Details | |
| 12/18/2024 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (N/A) |
|
Details | ||
| 12/11/2024 | Q32 Bio Inc. | QTTB | Downgrade | Equal Weight (Overweight) |
22.67 (4.70) |
-79.27% | Details | |
| 12/2/2024 | Kymera Therapeutics | KYMR | Upgrade | Overweight (Equal Weight) |
46.85 (83.49) |
78.21% | Details | |
| 11/6/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/1/2024 | Zymeworks | ZYME | Downgrade | Equal Weight (Overweight) |
13.70 (17.67) |
28.98% | Details | |
| 10/31/2024 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2024 | Acelyrin Inc | SLRN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/15/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 10/1/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/25/2024 | Celldex Therapeutics | CLDX | Upgrade | Overweight (Equal Weight) |
40.96 (29.43) |
-28.15% | Details | |
| 9/11/2024 | Q32 Bio Inc. | QTTB | New Coverage | Overweight (N/A) |
47.96 (4.70) |
-90.2% | Details | |
| 8/12/2024 | Ventyx Biosciences Inc | VTYX | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Zentalis Pharmaceuticals | ZNTL | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/12/2024 | Kymera Therapeutics | KYMR | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/12/2024 | Celldex Therapeutics | CLDX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 8/12/2024 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 8/12/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 7/8/2024 | Acelyrin Inc | SLRN | Upgrade | Overweight (Equal Weight) |
4.06 (2.27) |
-44.09% | Details | |
| 6/18/2024 | Zentalis Pharmaceuticals | ZNTL | Downgrade | Equal Weight (Overweight) |
8.39 (2.30) |
-72.59% | Details | |
| 6/5/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/23/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/16/2024 | Sutro Biopharma | STRO | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/15/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | C4 Therapeutics | CCCC | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/9/2024 | Arvinas Inc. | ARVN | Maintain | Overweight (N/A) |
|
Details | ||
| 5/9/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/3/2024 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 5/3/2024 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2024 | Annexon Biosciences | ANNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/20/2024 | Acelyrin Inc | SLRN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/12/2024 | Ventyx Biosciences Inc | VTYX | Upgrade | Overweight (Equal Weight) |
8.04 (14.00) |
74.13% | Details | |
| 3/12/2024 | Zymeworks | ZYME | Maintain | Overweight (N/A) |
|
Details | ||
| 2/29/2024 | Ventyx Biosciences Inc | VTYX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/29/2024 | Viridian Therapeutic | VRDN | Maintain | Overweight (N/A) |
|
Details | ||
| 2/28/2024 | Celldex Therapeutics | CLDX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/23/2024 | Kymera Therapeutics | KYMR | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/23/2024 | C4 Therapeutics | CCCC | Maintain | Equal Weight (N/A) |
|
Details | ||
| 2/16/2024 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/17/2024 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2023 | Ventyx Biosciences Inc | VTYX | Maintain | Equal Weight (N/A) |
|
Details | ||
| 12/19/2023 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 12/19/2023 | Arvinas Inc. | ARVN | Upgrade | Overweight (Equal Weight) |
35.43 (13.60) |
-61.61% | Details | |
| 12/14/2023 | Apellis Pharmaceuticals | APLS | Downgrade | Equal Weight (Overweight) |
62.88 (23.15) |
-63.18% | Details | |
| 11/10/2023 | Celldex Therapeutics | CLDX | Upgrade | Equal Weight (Underweight) |
25.78 (29.43) |
14.16% | Details | |
| 11/9/2023 | Arvinas Inc. | ARVN | Maintain | Equal Weight (N/A) |
|
Details | ||
| 11/2/2023 | Apellis Pharmaceuticals | APLS | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2023 | Blueprint Medicines | BPMC | Maintain | Overweight (N/A) |
|
Details | ||
| 10/16/2023 | Nurix | NRIX | Maintain | Overweight (N/A) |
|
Details | ||
| 9/15/2023 | Apellis Pharmaceuticals | APLS | Upgrade | Overweight (Equal Weight) |
43.31 (20.07) |
-53.66% | Details | |
| 7/31/2023 | Blueprint Medicines | BPMC | Upgrade | Overweight (Equal Weight) |
63.12 (129.46) |
105.1% | Details | |
| 7/20/2023 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 6/14/2023 | Blueprint Medicines | BPMC | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/16/2023 | Horizon Therapeutics | HZNP | Maintain | Equal Weight (N/A) |
|
Details | ||
| 5/5/2023 | Apellis Pharmaceuticals | APLS | Maintain | Equal Weight (N/A) |
|
Details | ||
| 3/21/2023 | Sutro Biopharma | STRO | New Coverage | Equal Weight (N/A) |
5.22 (25.29) |
384.48% | Details | |
| 3/21/2023 | Zymeworks | ZYME | New Coverage | Overweight (N/A) |
8.36 (24.08) |
188.04% | Details | |
| 1/3/2023 | Blueprint Medicines | BPMC | Upgrade | Equal Weight (Underweight) |
43.00 (129.46) |
201.07% | Details | |
| 1/3/2023 | Arvinas Inc. | ARVN | Downgrade | Equal Weight (Overweight) |
34.42 (13.60) |
-60.49% | Details | |
| 1/3/2023 | Apellis Pharmaceuticals | APLS | Downgrade | Equal Weight (Overweight) |
51.52 (20.07) |
-61.04% | Details | |
| 10/20/2022 | Cheniere Energy Partners, LP | CQP | Maintain | Underweight (N/A) |
|
Details | ||
| 5/31/2022 | Cheniere Energy Partners, LP | CQP | Downgrade | Underweight (Equal Weight) |
55.22 (62.89) |
13.89% | Details | |
| 5/31/2022 | Nurix | NRIX | Upgrade | Overweight (Equal Weight) |
9.02 (15.10) |
67.41% | Details |
